Moderna Forecast, price target & analysts
Moderna Target price 2026 - Analyst rating & recommendation
Moderna Classifications & Recommendation
Moderna Price Target
| Target Price | $132.60 |
| Price | $223.37 |
| Deviation | 40.64% |
| Number of Estimates | 23 |
| 23 Analysts have issued a price target Moderna 2027 . The average Moderna target price is $132.60. This is 40.64% lower than the current stock price. The highest price target is $263.55 17.99% , the lowest is $45.45 79.65% . | |
| A rating was issued by 31 analysts: 10 Analysts recommend Moderna to buy, 17 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Moderna stock has an average upside potential 2027 of 40.64% . Most analysts recommend the Moderna stock at Hold. |
Sales and Margin forecast 2026, 2027 to 2033
28 Analysts have issued a sales forecast Moderna 2026 . The average Moderna sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
16 Analysts have issued an Moderna EBITDA forecast 2026. The average Moderna EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
29 Moderna Analysts have issued a net profit forecast 2026. The average Moderna net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
Current Moderna Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Nov 09 2026 |
| Goldman Sachs |
Neutral
➜
Neutral
|
Unchanged | Nov 09 2026 |
| William Blair |
Outperform
➜
Market Perform
|
Downgrade | Oct 27 2026 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Oct 26 2026 |
| TD Cowen |
Hold
➜
Hold
|
Unchanged | Oct 21 2026 |
| Goldman Sachs |
Neutral
➜
Neutral
|
Unchanged | Oct 15 2026 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Nov 09 2026 |
|
Unchanged
Goldman Sachs:
Neutral
➜
Neutral
|
Nov 09 2026 |
|
Downgrade
William Blair:
Outperform
➜
Market Perform
|
Oct 27 2026 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Oct 26 2026 |
|
Unchanged
TD Cowen:
Hold
➜
Hold
|
Oct 21 2026 |
|
Unchanged
Goldman Sachs:
Neutral
➜
Neutral
|
Oct 15 2026 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Oct 07 2026 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
